BOULDER, Colo.–(BUSINESS WIRE)–Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of SHORTEN-ctDNA, a clinical trial at Columbia University.1 The study aims to evaluate the ability to utilize Foresight CLARITY™ MRD detection to enable real-time treatment optimization for patients with diffuse large B-cell lymphoma (DLBCL). Currently the standard treatment for newly diagnosed DLBCL requires six cycles of combinatio
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
